Low riskFDA DrugClass III

Ascend Laboratories dabigatran capsules recalled for impurity levels

Ascend Laboratories is recalling one lot of dabigatran etexilate 75 mg capsules, sold in 30-count blister packs, because testing found impurity levels outside specifications at the 12-month stability point. The recall covers 936 cartons distributed nationwide by Major Pharmaceuticals. No injuries have been reported.

From the FDA notice · Read the official notice ↗ · All Ascend Laboratories recalls

What to do

  1. Talk to your pharmacist or prescriber before stopping this medicine.
  2. Check whether your carton or blister pack shows lot 25141586, expiration April 30, 2027, and NDC 0904-7253-04.
  3. The notice doesn't say how to get a refund or replacement; ask your pharmacy or contact Ascend Laboratories.

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Dabigatran Etexilate Capsules, 75 mg, 30-count (3x10) blister pack further packaged in a carton, Rx only, Manufactured by: Alkem Laboratories Ltd., Mumbai, INDIA, Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268, NDC 0904-7253-04.
Sold in
Nationwide
Made for
Adults (0 months and older)

This recall covers 3 products — see all of them.

Details

Units affected
936 cartons x 12 x 3 x 10 (in blister pack)
Illnesses reported
None reported
Manufactured in
135 Us Highway 202 206 Ste 15, N/A, Bedminster, NJ, United States
Classification
Class III
Recall number
D-0739-2026

In the FDA's words

Description
Dabigatran Etexilate Capsules, 75 mg, 30-count (3x10) blister pack further packaged in a carton, Rx only, Manufactured by: Alkem Laboratories Ltd., Mumbai, INDIA, Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268, NDC 0904-7253-04. Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability Lot: 25141586, Exp. April 30, 2027. Distribution: USA Nationwide Affected quantity: 936 cartons x 12 x 3 x 10 (in blister pack)
Hazard
Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability

3 products in this recall

The agency lists each product separately. Check every one you might have.

More from Ascend Laboratories

See all

Related topics

Industrial chemicalsPotencyDrugsSold nationwideMore from FDA Drug